title: Immunogenicity of recombinant classic swine fever virus CD8(+) T lymphocyte epitope and porcine parvovirus VP2 antigen coexpressed by Lactobacillus casei in swine via oral vaccination.
abstract: Classical swine fever virus (CSFV) and porcine parvovirus (PPV) are highly contagious pathogens, resulting in enormous economic losses in pig industries worldwide. Because vaccines play an important role in disease control, researchers are seeking improved vaccines that could induce antiviral immune responses against CSFV and PPV at the mucosal and systemic levels simultaneously. In this study, a genetically engineered Lactobacillus strain coexpressing the CSFV-specific cytotoxic T lymphocyte (CTL) epitope 290 and the VP2 antigen of PPV was developed, and its immunopotentiating capacity as an oral vaccine in pigs was analyzed. The data demonstrated that in the absence of any adjuvant, the recombinant Lactobacillus strain can efficiently stimulate mucosal and systemic CSFV-specific CD8(+) CTL responses to protect pigs against CSFV challenge. Moreover, anti-PPV-VP2 serum IgG and mucosal IgA were induced in pigs immunized orally with the recombinant Lactobacillus strain, showing a neutralizing effect on PPV infection. The results suggest that the recombinant Lactobacillus microecological agent may be a valuable component of a strategy for development of a vaccine against CSFV and PPV.
authors.affiliation: Veterinary Department, Northeast Agricultural University, Mu Cai Street 59, Xiang Fang District, Harbin, People's Republic of China.
authors.forename: Yigang
authors.initials: Y
authors.lastname: Xu
authors.forename: Lichun
authors.initials: L
authors.lastname: Cui
authors.forename: Changyong
authors.initials: C
authors.lastname: Tian
authors.forename: Guocai
authors.initials: G
authors.lastname: Zhang
authors.forename: Guicheng
authors.initials: G
authors.lastname: Huo
authors.forename: Lijie
authors.initials: L
authors.lastname: Tang
authors.forename: Yijing
authors.initials: Y
authors.lastname: Li
mesh_terms: D000284:Administration, Oral; D000818:Animals; D057134:Antibodies, Neutralizing / Q000032:analysis / Q000097:blood; D000914:Antibodies, Viral / Q000032:analysis / Q000097:blood; D000956:Antigens, Viral / Q000235:genetics / Q000276:immunology*; D001769:Blood / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology*; D006691:Classical Swine Fever / Q000401:mortality / Q000473:pathology / Q000517:prevention & control; D006692:Classical Swine Fever Virus / Q000235:genetics / Q000276:immunology*; D004337:Drug Carriers / Q000008:administration & dosage*; D018984:Epitopes, T-Lymphocyte / Q000235:genetics / Q000276:immunology*; D005822:Genetic Vectors / Q000008:administration & dosage; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000097:blood; D007413:Intestinal Mucosa / Q000276:immunology; D007780:Lacticaseibacillus casei / Q000235:genetics*; D016019:Survival Analysis; D013552:Swine; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D000956:Antigens, Viral; D036022:Capsid Proteins; D004337:Drug Carriers; D018984:Epitopes, T-Lymphocyte; D007070:Immunoglobulin A; D007074:Immunoglobulin G; C528774:VP2 protein, porcine parvovirus; D014614:Vaccines, Synthetic; D014765:Viral Vaccines